Log in
NASDAQ:KROS

Keros Therapeutics News Headlines

$53.91
+1.22 (+2.32 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$52.03
Now: $53.91▼
$54.58
50-Day Range
$36.00
MA: $44.92▼
$52.69
52-Week Range
$19.10
Now: $53.91▼
$65.50
Volume42,622 shs
Average Volume98,668 shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Keros Therapeutics (NASDAQ KROS) News Headlines Today

Source:
DateHeadline
Dosing underway for Keros Therapeuticss KER-050 in mid-stage for myelodysplastic syndromes studyDosing underway for Keros Therapeutics's KER-050 in mid-stage for myelodysplastic syndromes study
seekingalpha.com - October 20 at 2:11 PM
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
finance.yahoo.com - October 20 at 9:11 AM
Keros Therapeutics (NASDAQ:KROS) Trading Up 7.7%Keros Therapeutics (NASDAQ:KROS) Trading Up 7.7%
americanbankingnews.com - October 16 at 7:05 PM
Keros Therapeutics (NASDAQ:KROS) Trading 15.8% Higher Keros Therapeutics (NASDAQ:KROS) Trading 15.8% Higher
americanbankingnews.com - October 8 at 6:40 PM
Passage Bio (NASDAQ:KROS) Given Average Rating of "Hold" by BrokeragesPassage Bio (NASDAQ:KROS) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - October 1 at 3:44 AM
Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceKeros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 14 at 9:46 AM
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual MeetingKeros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
finance.yahoo.com - September 11 at 4:40 PM
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial ResultsKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
finance.yahoo.com - August 13 at 9:48 AM
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease SeriesKeros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
finance.yahoo.com - August 10 at 12:38 PM
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program UpdateKeros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
finance.yahoo.com - August 4 at 1:01 PM
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn SituationHere's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
finance.yahoo.com - July 29 at 2:26 PM
Keros Therapeutics Set to Join Russell 2000® IndexKeros Therapeutics Set to Join Russell 2000® Index
finance.yahoo.com - June 26 at 8:06 AM
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual MeetingKeros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
finance.yahoo.com - June 12 at 9:57 AM
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare ConferenceKeros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
finance.yahoo.com - May 28 at 8:07 AM
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial ResultsKeros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
finance.yahoo.com - May 22 at 9:42 AM
3 Biotech Stocks With Plenty of Upside in the Pipeline3 Biotech Stocks With Plenty of Upside in the Pipeline
finance.yahoo.com - May 5 at 3:35 PM
This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.